二、监事会会议审议情况 证券代码：300760 证券简称：迈瑞医疗 公告编号：2024-045 深圳迈瑞生物医疗电子股份有限公司 第八届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、监事会会议召开情况 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）第八届监事会第八次会议于 2024年10月29日在迈瑞总部大厦会议室以现场表决方式召开，会议通知于2024年10月25日 以电子邮件等方式送达全体监事。 会议由公司监事会主席汤志先生主持。本次会议应出席监事3人，实际到会监事3人。本 次会议的召集、召开符合《中华人民共和国公司法》和《深圳迈瑞生物医疗电子股份有限公 司章程》（以下简称"《公司章程》"）等有关规定。 经与会监事充分讨论，本次会议审议并通过了如下议案： 1、审议通过《关于<2024年第三季度报告>的议案》 经审议，监事会认为：董事会编制和审核《2024年第三季度报告》的程序符合法律、行 政法规、中国证监会和深圳证券交易所的规定，报告内容真实、准确、完整地反映了公司 2024年前三季度经营的实际情况，不存在任何虚假记载、 ...

核查意见 华泰联合证券有限责任公司 关于深圳迈瑞生物医疗电子股份有限公司 继续使用部分闲置募集资金进行现金管理的核查意见 为持续提高深圳迈瑞生物医疗电子股份有限公司（以下简称"迈瑞医疗"、 "上市公司"、"公司"）及子公司资金利用效率，继续合理利用闲置募集资金， 优化经济效益，公司于 2024 年 10 月 29 日召开第八届董事会第十次会议及第八 届监事会第八次会议，审议通过了《关于继续使用部分闲置募集资金进行现金管 理的议案》，同意在确保募集资金安全和不影响公司正常经营的情况下，继续使 用闲置募集资金进行现金管理，购买安全性高、流动性好的存款类产品或保本型 产品，包括但不限于大额存单、定期存款、结构性存款、通知存款、协定存款、 短期保本型产品等，使用期限自董事会审议通过之日起至 2025 年 10 月 31 日内 有效，有效期内业务实施总额不超过 6.37 亿元（含本数）。在上述额度及决议有 效期内，业务可循环滚动开展。 华泰联合证券有限责任公司（以下简称"华泰联合证券"、"保荐机构"）作 为迈瑞医疗首次公开发行股票并在创业板上市持续督导阶段的保荐机构，根据 《证券发行上市保荐业务管理办法》《上市公司监管 ...

证券代码：300760 证券简称：迈瑞医疗 公告编号：2024-048 关于会计政策变更的公告 2、变更日期 公司自 2024 年 1 月 1 日起开始执行。 深圳迈瑞生物医疗电子股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 深圳迈瑞生物医疗电子股份有限公司（下称"公司"）本次会计政策变更是根据国家 统一的会计制度要求作出的变更，无需提交公司董事会和股东大会审议，对公司财务状况、 经营成果和现金流量无重大影响，不存在损害公司及全体股东利益的情形。 一、本次会计政策变更的概述 1、变更原因 2024 年 3 月，财政部会计司编写并发行了《企业会计准则应用指南汇编 2024》，其中 明确了企业因保证类质量保证产生的预计负债，应当按确定的金额，借记"主营业务成 本"、"其他业务成本"等科目，贷记"预计负债"科目。根据上述规定和要求，公司需 对原采用的相关会计政策进行相应变更。 二、本次会计政策变更对公司的影响 公司自 2024 年 1 月 1 日起执行《企业会计准则应用指南汇编 2024》中关于保证类质量 保证的会计处理规定，按确定的金额 ...

证券代码：300760 证券简称：迈瑞医疗 公告编号：2024-044 深圳迈瑞生物医疗电子股份有限公司 第八届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）第八届董事会第十次会议于 2024年10月29日上午10:10在安徽砀山以现场加通讯表决相结合的方式召开，会议通知于 2024年10月25日以电子邮件等方式送达全体董事。 会议由公司董事长李西廷先生主持。本次会议应出席董事人数11人，实际出席董事人数 11人，其中董事徐航先生以通讯表决方式参会。本次会议的召集、召开符合《中华人民共和 国公司法》（以下简称"《公司法》"）和《深圳迈瑞生物医疗电子股份有限公司章程》（以下 简称"《公司章程》"）等有关规定。 二、董事会会议审议情况 经与会董事充分讨论，本次会议审议并通过了如下议案： 1、审议通过《关于<2024年第三季度报告>的议案》 经审议，董事会编制和审核的《2024年第三季度报告》，符合法律、行政法规、中国证 监会和深圳证券交易所的规定，报告内容真实、 ...

迈瑞医疗：第三季度净利润30.76亿元 同比下降9.31% 财联社10月29日电，迈瑞医疗发布2024年第三季 度报告，前三季度公司实现营业收入294.85亿元，同比增长7.99%；净利润106.37亿元，同比增长 8.16%。 其中，第三季度实现营业收入89.54亿元，同比增长1.43%；净利润30.76亿元，同比下降9.31%。 查看公告原文 ...

证券代码：300760 证券简称：迈瑞医疗 公告编号：2024-042 深圳迈瑞生物医疗电子股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）于近日接到公司控股股东 Magnifice（HK）Limited（以下简称"Magnifice（HK）"）的通知，获悉其将所持有的公司 部分股份办理了解除质押业务，现将具体内容公告如下： 一、 股东股份解除质押的基本情况 | | 是否为控 股股东或 | 本次解除质 | 占其所 | 占公司总 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | 第一大股 | 押股份数量 | 持股份 | 股本比例 | 起始日 | | 解除日期 | | 质权人 | | | 东及其一 | （股） | 比例 | | | | | | | | | 致行动人 | | | | | | | | | | Magnifice | | | | | 202 ...

Market Performance and Growth - North America revenue CAGR from 2020-2023 was 16%, significantly higher than the low single-digit industry growth rate [2] - North America accounted for 6% of the company's H1 2024 revenue, with expectations for this proportion to continue declining [3] - Domestic equipment business contributed 27% of total revenue in H2 2023, with performance dependent on equipment renewal implementation [3] - Overseas revenue accounted for 41% of total revenue in H2 2023, expected to maintain rapid growth, especially in developing countries and Europe [3] Product and Market Strategy - The company has secured a three-year exclusive anesthesia machine supply agreement with the 10th largest IDN in the US [2] - Currently offering 3 product categories in the US market, with plans to expand from the existing 30 sub-product categories [3] - Achieved top 3 market share for key products in the US, including patient monitors, anesthesia machines, and POC ultrasound [2] - The company aims to enter the global top 20 medical device companies by 2025 [3] International Expansion - European market showing recovery, with breakthrough contracts at top hospitals including St Thomas' Hospital (UK), Charité - Universitätsmedizin Berlin (Germany), and Hôpital de la Pitié-Salpêtrière (France) [5] - Developing countries emerging as a major growth driver, with over one-third of revenue coming from IVD business [6] - Established localized production in 12 countries across major markets, with 9 facilities related to IVD production [6] AI and Technological Innovation - AI-powered blood cell morphology analyzer reduced average slide review time from 25-30 minutes to 30 seconds [6] - The MC series AI-powered blood cell analyzer has been installed in over 400 hospitals globally, surpassing competitor's decade-long sales within one year [7] - Collaborated with Tencent to develop a critical care domain model, currently being tested in top-tier Chinese hospitals [7] Policy and Market Environment - The Chinese government has allocated 300 billion RMB in ultra-long-term special treasury bonds to support medical equipment renewal [4] - Domestic equipment renewal projects have been approved, with hospital tendering processes expected to commence upon fund allocation [4] - The company has observed accelerated issuance of local government special bonds, supporting medical equipment procurement [3] M&A Strategy - The company has accelerated M&A activities since 2008, focusing on core technology enhancement, new business exploration, and overseas market expansion [4] - Recent M&A activities emphasize strengthening existing businesses and exploring new areas rather than merely expanding revenue [4] - Future M&A will focus on acquiring cutting-edge technologies and enhancing global R&D, marketing, and supply chain platforms [4]

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 335 yuan, while the current price is 231.67 yuan [2][3]. Core Insights - The company reported a robust performance in its 2024 mid-year report, with total revenue of 20.531 billion yuan, an increase of 11.12%, and a net profit attributable to shareholders of 7.561 billion yuan, up 17.37% [2]. - The IVD (In Vitro Diagnostics) business showed outstanding growth, achieving revenue of 7.658 billion yuan in the first half of 2024, a year-on-year increase of 28.16%, driven by strong overseas penetration and domestic demand [3]. - The Life Information and Support segment generated revenue of 8.009 billion yuan, although it experienced a decline of 7.59% overall, with significant growth in minimally invasive surgery and high-value consumables [3]. - The Medical Imaging segment reported revenue of 4.274 billion yuan, a growth of 15.49%, with high-end ultrasound models seeing over 40% revenue growth [3]. - The company expects net profit attributable to shareholders to reach 13.748 billion yuan, 16.443 billion yuan, and 19.529 billion yuan for 2024, 2025, and 2026, respectively, reflecting year-on-year growth rates of 18.7%, 19.6%, and 18.8% [3]. Financial Summary - Total revenue for 2023 is projected at 34.932 billion yuan, with a growth rate of 15.0%, and net profit is expected to be 11.582 billion yuan, with a growth rate of 20.6% [4]. - The company’s earnings per share (EPS) for 2024 is estimated at 11.34 yuan, with a price-to-earnings (P/E) ratio of 20 [4]. - The company’s total market capitalization is approximately 280.886 billion yuan, with a debt-to-equity ratio of 13.8% [7].

Investment Rating - The report initiates coverage with a "Buy" rating for the company [2]. Core Views - The company has established a comprehensive product line in the medical device industry, leveraging a dual strategy of self-research and external acquisitions to drive growth. The aging population and supportive policies are expected to expand market demand, allowing the company to maintain high growth rates even with a revenue scale of 30 billion RMB [2]. - The company leads in the life information and support sector, with significant market shares in various products, including monitoring devices and anesthesia machines, achieving global top-three positions in certain categories [2]. - The in vitro diagnostics (IVD) business is rapidly increasing its market share due to domestic procurement policies and integrated supply chain strategies, with expectations for further expansion in both domestic and international markets [2]. - The medical imaging segment is transitioning from low-end to high-end products, with a projected CAGR of 5.0% for the ultrasound market in China, indicating strong growth potential [2]. - Emerging sectors, including minimally invasive surgery and animal healthcare, are being cultivated, contributing to new revenue streams for the company [2]. - Valuation analysis indicates that the company is currently undervalued compared to historical levels and peers, suggesting potential for price appreciation [2]. Summary by Sections Company Overview - Founded in 1991, the company has developed a full product line in the medical device sector, focusing on safety, efficiency, and ease of use to meet clinical needs [7]. Core Business Segments - **Life Information and Support**: The company has achieved leading positions in various product categories, with significant breakthroughs in high-end customer penetration [36]. - **In Vitro Diagnostics**: The company is expanding its market share through domestic procurement policies and has integrated its supply chain to enhance competitiveness [45]. - **Medical Imaging**: The company is focusing on high-end ultrasound products, with a current market share of approximately 24% in China and 8% globally [2][36]. Emerging Sectors - The company has been developing new business areas since 2012, including minimally invasive surgery and animal healthcare, which are expected to contribute to future growth [2]. Financial Projections - Revenue forecasts for 2024-2026 are 41.17 billion, 49.17 billion, and 58.60 billion RMB, with corresponding growth rates of 17.8%, 19.4%, and 19.2% [3]. - Net profit forecasts for the same period are 13.63 billion, 16.38 billion, and 19.75 billion RMB, with growth rates of 17.7%, 20.2%, and 20.6% [3]. Valuation Analysis - The company's current PE ratio is at historical lows, indicating a favorable investment opportunity compared to its market position and growth prospects [2].

Investment Rating - Buy (Maintained) [1] Core Views - The company's 24H1 performance met expectations, with significant growth in the IVD (In Vitro Diagnostics) business [2] - Revenue for 24H1 reached 20.53 billion yuan (+11.1%), with net profit attributable to the parent company at 7.56 billion yuan (+17.4%) [2] - The IVD business grew by 28.2% in 24H1, driven by strong demand in both domestic and international markets [2] - The company continues to invest heavily in R&D, with 1.78 billion yuan spent in 24H1, focusing on high-end product innovation and expanding the "Ruizhilien" ecosystem [2] Business Performance Life Information & Support - Revenue for 24H1 was 8.01 billion yuan (-7.6%), with significant growth in minimally invasive surgery and high-value consumables [2] - Domestic market faced delays due to healthcare industry reforms, but international demand has recovered, leading to double-digit growth [2] In Vitro Diagnostics (IVD) - Revenue for 24H1 was 7.65 billion yuan (+28.2%), with chemical发光业务增长超过30% [2] - Domestic IVD business grew over 25%, with blood cell business growing over 30% [2] - International IVD business grew over 30%, with successful penetration into over 60 overseas third-party laboratories [2] Medical Imaging - Revenue for 24H1 was 4.27 billion yuan (+15.5%), with high-end ultrasound models growing over 40% [2] - Domestic market faced challenges due to industry reforms, but the company increased investment in high-end international markets [2] Financial Projections - Expected net profit attributable to the parent company for 2024-2026 is 13.75 billion, 16.65 billion, and 19.95 billion yuan, respectively [2] - EPS for 2024-2026 is projected to be 11.34, 13.73, and 16.45 yuan, with PE ratios of 22, 18, and 15 times, respectively [2] Market Performance - The stock's relative performance compared to the CSI 300 index shows a decline of 16% over the past year [4] - The company's total market capitalization is 300.07 billion yuan, with a total asset value of 60.63 billion yuan [5]